Clinical Manifestations of Excessive Use of Ergotamine Preparations and Management of Withdrawal Effect: Report of 52 Cases

Horton, Bayard T.; Peters, Gustavus A.

doi:10.1111/j.1526-4610.1963.hed0204214.x

Cited by 73 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the patient then begins to find that the period of time in which there is relief from the medication begins to diminish, and the amount of medication used continues to increase. The patient may find, as in the case of Horton and Peters [5•,Class IIIa2], that there is some headache present much of the time. The patient also finds that despite increasing use of the medication, the overall headache problem, as measured by the amount of pain and amount of interference with the patient's daily life, is steadily worsening.…”

Section: Descriptionmentioning

confidence: 94%

See 1 more Smart Citation

Rebound-withdrawal headache (medication overuse headache)

Couch

2006

Curr Treat Options Neurol

View full text Add to dashboard Cite

Rebound-withdrawal headache (medication overuse headache) is a problem that affects 1% of the population or perhaps more. Work from many countries has shown this to be a worldwide problem. It appears that the rebound-withdrawal headache often occurs on the background of pre-existing migraine or tension headache and may assume the phenotype of chronic migraine or chronic tension-type headache. The key feature of this entity is that the patient initially uses a symptomatic treatment for headache with good result. Use of this medication may increase over time, but as the use increases to more than 10 to 15 days per month, headache frequency may also increase, reaching a point where metabolic processing of the medication and removal from the system triggers another headache. The patient then finds that as use of the medication increases, the frequency and intensity of the headaches also increases, and the overall headache worsens. Once this pattern is established, therapy requires removal of the medication in order for the rebounding process to be terminated. Preventative antimigraine medications will not work in the presence of the rebound phenomenon. Once the rebound-withdrawal headache is established, it is difficult to treat. After withdrawal of the medication, there is often a high relapse rate of using the medication again with redevelopment of the rebound-withdrawal headache. Even in patients who do not relapse to drug use, headache usually remains a major problem. Recognition and treatment of rebound headache are key factors in management of these patients. Perhaps more important in regard to this entity is recognizing its existence and preventing patients from entering a pattern of rebound withdrawal, which can be achieved by early attention to their use of analgesic narcotic or migraine-abortive medications. Overall, it is likely that this will continue to be an increasing worldwide problem in managing patients with headache.

show abstract

Section: Descriptionmentioning

confidence: 94%

“…In 1955, Friedman et al [4] noted withdrawal headache in their patients. In 1963, Horton and Peters [5•,Class IIIa2] published a follow-up on 52 patients who were using large amounts of ergotamine. They noted rebound headache in 32 patients, including 18 of 25 with migraine tension headache, and six of six with "tension headache."…”

Section: Opinion Statementmentioning

confidence: 99%

Rebound-withdrawal headache (medication overuse headache)

Couch

2006

Curr Treat Options Neurol

View full text Add to dashboard Cite

show abstract

“…Horton u. Peters [34] und Peters u. Horton [57] beschrieben als Erste eine Chronifizierung der Migräne durch die zu häufige Einnahme von Mutterkornalkaloiden. Dichgans et al…”

Section: Chronische Migräneunclassified

Aktuelle Diagnostik und Therapie der Migräne

Diener

Katsarava

Limmroth

2008

Schmerz

View full text Add to dashboard Cite

Headaches are one of the most common disorders and symptoms in daily medical practice. The prevalence of migraine is 8% in men and 12-15% in women. Dramatic progress in the areas of epidemiology, pathophysiology, and acute and preventive therapy of migraine has been made over the past 100 years, with triptans being the breakthrough for treating acute migraine attacks. Beta blockers, calcium antagonists, and neuromodulators are available for preventive migraine therapy. Nonpharmacologic treatment also plays an important role in migraine prevention. New medical care structures such as integrated headache care provide better support for patients with migraine, particularly those with chronic migraine.

show abstract

“…This was first recognized by Peters and Horton [11] in 1950 and later by Friedman et al [12] in 1955. MOH is an entity related to the overuse of symptomatic medication (SM), which in turn exacerbates the headache problem [1,9,10,13]. The IHS classification recognizes MOH related to ergotamines, triptans, analgesics, opioids, and combination medications in addition to "other medication overuse" [1].…”

Section: Medication-overuse Headachementioning

confidence: 99%

The long-term prognosis of tension-type headache

Couch

2005

Current Science Inc

View full text Add to dashboard Cite

Tension-type headache (TTH) is a very common problem that usually causes only minimal to moderate discomfort and little disability. If episodic TTH evolves to chronic TTH, then the morbidity in terms of discomfort, disability, and use of medication escalates dramatically. There are no long-term studies, but inferences can be made from population surveys. These suggest that episodic TTH occurs in 15% to 75% of the population, but 30% to 40% is the most common estimate. There is a modest increase in prevalence between the ages of 30 and 50 years and a decrease to 25% to 35% prevalence after the age of 60 years. TTH appears to remain a problem for most sufferers throughout their lives.

show abstract

Clinical Manifestations of Excessive Use of Ergotamine Preparations and Management of Withdrawal Effect: Report of 52 Cases

Cited by 73 publications

References 0 publications

Rebound-withdrawal headache (medication overuse headache)

Rebound-withdrawal headache (medication overuse headache)

Aktuelle Diagnostik und Therapie der Migräne

The long-term prognosis of tension-type headache

Contact Info

Product

Resources

About